Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Melanotan I cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established Melanotan I cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Melanotan I combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Melanotan I cycle length?
No. We found no human studies that report a treatment duration for Melanotan I.
What is the longest human study of Melanotan I?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Melanotan I dosing reference Full research page

References

  1. SCENESSE (afamelanotide) implant, for subcutaneous use. Prescribing information, CLINUVEL Inc. (SPL published May 13, 2026) DailyMed (FDA label). 2026
  2. Drugs@FDA application record for SCENESSE (afamelanotide), NDA 210797, original approval 8 October 2019 openFDA / Drugs@FDA. 2026
  3. Scenesse (afamelanotide): EPAR, medicine overview (authorised 22 December 2014 under exceptional circumstances) European Medicines Agency. 2026
  4. Afamelanotide for Erythropoietic Protoporphyria N Engl J Med. 2015